Drug development shouldn’t be guesswork, not when patients are waiting.
Pathos is an AI and technology company that develops drugs. Foundry, our platform,
decides which ones.
We are not a biotech that uses AI. We are redesigning drug development from first
principles around an AI and technology core. Our Foundation Model reads across DNA,
RNA, pathology, and clinical text on 200+ petabytes of Multimodal data. Our Foundry
platform turns that model into live portfolio decisions: which asset to invest in, which trial
design to pivot, which program to stop. In 2026, every major portfolio decision
at Pathos was Foundry-informed, a Platform-Informed Decisions score of 4 out of 4.
The three engines of the platform are Scout (finds assets other companies would miss),
Foundry (decides where capital and clinical attention go), and Sprint (executes trials with
AI agents doing the work that used to require a full biotech). We call it a biotech
company in a box.
We are well-capitalized. We have three clinical-stage oncology programs, and a co-development partnership with a top-five pharma. Our leadership has
nearly two decades of company-building experience and multiple successful exits behind
them.
How We Build
Pathos does not operate like a traditional biotech. There is no middle management.
There are no layers of approval. Every function, Clinical, Legal, Finance, Regulatory,
Engineering, Research, is built the same way: small teams of 3-5 subject matter experts,
each commanding 30-50 AI agents to do the work that used to require dozens of people.
Everyone builds. Everyone ships. Product velocity is measured in hours, not weeks. A team of 40-50 operators does the work of a traditional biotech of 300. Every dollar saved
on overhead is a dollar deployed into a clinical program.
The people who thrive here are operators: deep experts who can specify what needs to
happen, orchestrate AI agents to execute at scale, and make high-judgment calls that
compound over time. If you have spent your career building and shipping in your
domain, this is the environment where that experience becomes a superpower.
We are seeking a Director, Clinical Operations Program Lead to own the operational strategy and end-to-end execution of our clinical programs. At Pathos, that does not mean building and running a large operations team. It means acting as the operator who sets clinical operational direction and commands a fleet of AI agents to carry it out, from study startup through database lock. You will translate asset strategy into executable trials, then orchestrate agentic systems to run the day-to-day: tracking timelines and enrollment, monitoring site and vendor performance, surfacing risks, and drafting the operational documentation that used to take a full team.
This is a foundational hire on the Pathos Clinical Operations team, reporting to the Chief Clinical Operations Officer and partnering closely with Clinical Development, Regulatory, Data Management, Biometrics, and Research. You are equally comfortable setting program-level strategy and getting into the detail of a single study. You know how to get a trial from concept to first-patient-in and through close-out, how to hold CROs and vendors accountable, and how to make the high-judgment calls that keep timelines, quality, and budget in balance, with AI agents handling the operational load so your time goes to the decisions that matter.
Program Strategy & Operational Leadership
Agent-Driven Trial Execution
Quality, Compliance & Cross-Functional Partnership
Required Qualifications
Preferred Qualifications
What Success Looks Like
This is a hybrid role, requiring 3 days per week onsite, in our NYC Headquarters.
Przedział wynagrodzenia na tym stanowisku wynosi:
180,000 - 200,000 USD na year (New York Office - ACLS East Tower)
Clinical
New York, NY
Udostępnij w: